Detecting peritoneal dissemination of ovarian cancer in mice by DWIBS

Lee, Hye Jeong; Luci, Jeffrey J.; Tantawy, Mohammed Noor; Lee, Haakil; Nam, Ki Taek; Peterson, Todd E.; Price, Ronald R.

doi:10.1016/j.mri.2012.06.016

Cited by 12 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 50 However, DWI is vulnerable to physiological motion present in the abdomen. 51 The employment of FR-targeted fluorescence and PET imaging agents in combination with MRI (e.g., PET/MRI) can lead to higher sensitivity than each modality, potentially resulting in the diagnosis of “low volume,” early stage EOC. 52…”

Section: Discussionmentioning

confidence: 99%

Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model

et al. 2015

View full text Add to dashboard Cite

A new transplantable ovarian tumor model is presented using a novel folate receptor (FR) positive, murine ovarian cancer cell line that emulates the human disease and induces widespread intraperitoneal (i.p.) tumors in immunocompetent mice within 4–8 weeks of implantation. Tumor development was monitored using a new positron emission tomography (PET) FR-targeting reporter with PET/computerized tomography (PET/CT) and fluorescence molecular tomography (FMT) using a commercial FR-targeting reporter. Conventional structural magnetic resonance imaging (MRI) was also performed. Adult female C57BL/6 mice were injected i.p. with 6 × 106 MKP-L FR+ cells. Imaging was performed weekly beginning 2 weeks after tumor induction. The albumin-binding, FR-targeting ligand cm09 was radiolabeled with the positron emitter 68Ga and used to image the tumors with a small animal PET/CT. The FR-reporter FolateRSense 680 (PerkinElmer) was used for FMT and flow cytometry. Preclinical MRI (7 T) without FR-targeting was compared with the PET and FMT molecular imaging. Tumors were visible by all three imaging modalities. PET/CT had the highest imaging sensitivity at 3–3.5 h postadministration (mean %IA/g mean > 6) and visualized tumors earlier than the other two modalities with lower kidney uptake (mean %IA/g mean < 17) than previously reported FR-targeting agents in late stage disease. FMT showed relatively low FR-targeted agent in the bladder and kidneys, but yielded the lowest anatomical image resolution. MRI produced the highest resolution images, but it was difficult to distinguish tumors from abdominal organs during early progression since a FR-targeting MRI reporter was not used. Nevertheless, there was good correlation of imaging biomarkers between the three modalities. Tumors in the mouse ovarian cancer model could be detected using FR-targeted imaging as early as 2 weeks post i.p. injection of tumor cells. An imaging protocol should combine one or more of the modalities, e.g., PET/CT or PET/MRI for optimal tumor detection and delineation from surrounding tissues.

show abstract

Section: Discussionmentioning

confidence: 99%

Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Peritoneal imaging in small animals is challenging, and only a few studies have shown the potential of CT imaging in rodents (microCT) for the detection of PM, due to a poor soft tissue contrast resolution and time-consuming acquisitions, thus limiting the use of IV contrast agents 58 . Imaging techniques with high contrast resolution such as MRI, optical imaging and PET CT are more widely used in small animal 58 , 61 - 64 . However, the main limitation of these modalities is the lack of specificity which can lead to an overestimation of tumor burden 65 .…”

Section: Discussionmentioning

confidence: 99%

“…24 Of note, only the gadolinium separation is based on its K-edge energy, while the iodine separation is based on a 2 components model (water and iodine). Therefore, 2 energy bins were set at 50.2 keV (51)(52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62)(63)(64) to coincide with the K-edge energy of gadolinium, the extra energy bins were set to better managing the photon count rate (64-72, 72-85, 85-120). Further technical details are provided in previous studies 33,42 .…”

Section: Spectral Photon Counting Computed Tomography (Spcct) the Spmentioning

confidence: 99%

Spectral photon-counting CT imaging of colorectal peritoneal metastases: initial experience in rats

Thivolet

Bonnot

Blanchet

et al. 2020

Sci Rep

View full text Add to dashboard Cite

computed tomography imaging plays a major role in the preoperative assessment of tumor burden by providing an accurate mapping of the distribution of peritoneal metastases (PM). Spectral Photon Counting Computed Tomography (SPCCT) is an innovative imaging modality that could overcome the current limitations of conventional CT, offering not only better spatial resolution but also better contrast resolution by allowing the discrimination of multiple contrast agents. Based on this capability, we tested the feasibility of SPCCT in the detection of PM at different time of tumor growth in 16 rats inoculated with CC531 cells using dual-contrast injection protocols in two compartments (i.e. intravenous iodine and intraperitoneal gadolinium or the reverse protocol), compared to surgery. For all peritoneal regions and for both protocols, sensitivity was 69%, specificity was 100% and accuracy was 80%, and the correlation with surgical exploration was strong (p = 0.97; p = 0.0001). No significant difference was found in terms of diagnostic performance, quality of peritoneal opacification or diagnostic quality between the 2 injection protocols. We also showed poor vascularization of peritoneal metastases by measuring low concentrations of contrast agent in the largest lesions using SPCCT, which was confirmed by immunohistochemical analyses. In conclusion, SPCCT using dualcontrast agent injection protocols in 2 compartments is a promising imaging modality to assess the extent of PM in a rat model. Peritoneal metastases (PM) are part of the natural history of most abdominal and gynecological malignancies and have long been considered as a terminal disease. Over the past decades, the development of cytoreductive surgery with or without intraoperative hyperthermal intraperitoneal chemotherapy (HIPEC) has led to an improvement in survival of selected patients with resectable disease 1-4. For colorectal cancer, this strategy has significantly improved oncology outcomes 4,5. The completeness of the cytoreductive surgery is a crucial endpoint and is directly associated with the extent and distribution of PM in the peritoneal cavity 6,7. However, this aggressive treatment is associated with substantial morbidity (30-40%) and a mortality rate that is reported to range from 0-10%, resulting in a further drastic selection of patients in the pre-treatment work-up 8,9. In this context, preoperative evaluation of the peritoneal tumor burden, although extremely challenging, is essential for the selection of eligible patients for curative treatment 10,11. Computed tomography (CT) remains the reference imaging modality to assess the extent of PM. Although magnetic resonance imaging (MRI) and positron emission tomography-CT (PET-CT) have good diagnostic performance in some PM etiologies, these modalities are mainly used as a complement to CT evaluation 10,12-17. However, even though CT imaging offers high spatial resolution and fast acquisition time, its main drawback is its lack of contrast resolution, leading to a significant underestimation ...

show abstract

“…Diffusion-weighted MRI was introduced as a non-invasive technique providing functional information for both staging and response monitoring of solid tumours (Roth et al , 2004; Thoeny et al , 2005; Moffat et al , 2006; Schubert et al , 2006; Vandecaveye et al , 2009; Wang et al , 2009; Oka et al , 2010). In first preclinical studies in Ewing sarcomas, diffusion-weighted imaging effectively predicted early response of single subcutaneous tumours to chemotherapy in mice before the onset of morphological changes (Reichardt et al , 2009), and in a mouse model of ovarian cancer, DWIBS had the potential to detect peritoneal tumour dissemination (Lee et al , 2013). In pilot clinical studies, WB-MRI with DWIBS was found useful for detecting metastatic tumours especially in the bone (Nakanishi et al , 2007; Manenti et al , 2012; Sommer et al , 2012).…”

Section: Discussionmentioning

confidence: 99%

Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging

et al. 2013

View full text Add to dashboard Cite

Background:Novel treatment strategies in Ewing sarcoma include targeted cellular therapies. Preclinical in vivo models are needed that reflect their activity against systemic (micro)metastatic disease.Methods:Whole-body magnetic resonance imaging (WB-MRI) was used to monitor the engraftment and dissemination of human Ewing sarcoma xenografts in mice. In this model, we evaluated the therapeutic efficacy of T cells redirected against the Ewing sarcoma-associated antigen GD2 by chimeric receptor engineering.Results:Of 18 mice receiving intravenous injections of VH-64 Ewing sarcoma cells, all developed disseminated tumour growth detectable by WB-MRI. All mice had lung tumours, and the majority had additional manifestations in the bone, soft tissues, and/or kidney. Sequential scans revealed in vivo growth of tumours. Diffusion-weighted whole-body imaging with background signal suppression effectively visualised Ewing sarcoma growth in extrapulmonary sites. Animals receiving GD2-targeted T-cell therapy had lower numbers of pulmonary tumours than controls, and the median volume of soft tissue tumours at first detection was lower, with a tumour growth delay over time.Conclusion:Magnetic resonance imaging reliably visualises disseminated Ewing sarcoma growth in mice. GD2-retargeted T cells can noticeably delay tumour growth and reduce pulmonary Ewing sarcoma manifestations in this aggressive disease model.

show abstract

Detecting peritoneal dissemination of ovarian cancer in mice by DWIBS

Cited by 12 publications

References 24 publications

Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model

Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model

Spectral photon-counting CT imaging of colorectal peritoneal metastases: initial experience in rats

Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging

Contact Info

Product

Resources

About